Lake Street Advisors Group LLC Acquires Shares of 24,292 Sera Prognostics, Inc. (NASDAQ:SERA)

Lake Street Advisors Group LLC bought a new position in Sera Prognostics, Inc. (NASDAQ:SERA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,292 shares of the company’s stock, valued at approximately $144,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SERA. StepStone Group LP acquired a new stake in shares of Sera Prognostics during the 4th quarter worth approximately $61,000. Sanders Morris Harris LLC purchased a new stake in Sera Prognostics during the first quarter worth $174,000. Rhumbline Advisers acquired a new stake in Sera Prognostics during the second quarter valued at $190,000. Twelve Points Wealth Management LLC purchased a new position in Sera Prognostics in the second quarter valued at $257,000. Finally, Bank of New York Mellon Corp raised its position in shares of Sera Prognostics by 100.2% in the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after acquiring an additional 75,441 shares during the period. 54.64% of the stock is owned by institutional investors and hedge funds.

Sera Prognostics Stock Up 0.7 %

SERA stock opened at $7.30 on Tuesday. Sera Prognostics, Inc. has a 52-week low of $1.56 and a 52-week high of $12.35. The firm has a market cap of $243.60 million, a P/E ratio of -6.82 and a beta of 1.03. The company’s 50-day simple moving average is $7.14 and its 200-day simple moving average is $8.31.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.08 million. Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 11,843.79%. During the same quarter in the prior year, the company posted ($0.34) EPS. On average, analysts anticipate that Sera Prognostics, Inc. will post -0.95 earnings per share for the current fiscal year.

Insider Activity at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 12,327 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total transaction of $91,466.34. Following the completion of the transaction, the chief executive officer now directly owns 856,918 shares in the company, valued at $6,358,331.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Austin Aerts sold 6,760 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total value of $50,159.20. Following the transaction, the chief financial officer now directly owns 303,721 shares of the company’s stock, valued at approximately $2,253,609.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Zhenya Lindgardt sold 12,327 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $7.42, for a total value of $91,466.34. Following the sale, the chief executive officer now owns 856,918 shares of the company’s stock, valued at $6,358,331.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,306 shares of company stock valued at $180,326. 15.80% of the stock is owned by company insiders.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.